Lipid particle compositions and pharmaceutical compositions
A lipid particle composition with panobinostat, using phospholipids and cholesterols, addresses the challenge of bone marrow targeting, achieving enhanced drug retention and therapeutic efficacy.
Patent Information
- Application Number
- JP2023121194
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2016-12-26
- Filing Date
- 2023-07-26
- Publication Date
- 2024-11-20
- Estimated Expiration
- 2037-12-26
AI Technical Summary
There is a lack of liposome compositions that effectively target panobinostat to bone marrow with high accumulation, limiting its therapeutic potential in cancer treatment.
A lipid particle composition containing panobinostat or its salt, composed of phospholipids and cholesterols, with a specific particle size and formulation that enhances bone marrow targeting, achieved through remote loading and controlled drug encapsulation.
The lipid particle composition exhibits high targeting ability to bone marrow, improving therapeutic index and cancer treatment efficacy by enhancing drug retention and accumulation.
Smart Images

Figure 0007587644000008 
Figure 0007587644000009 
Figure 0007587644000010
Abstract
Description
[Technical field]
[0001] The present invention relates to a lipid particle composition containing panobinostat or a salt thereof, and a pharmaceutical composition comprising the lipid particle composition. [Background technology]
[0002] Panobinostat is a hydroxamic acid derivative used to treat multiple myeloma and is a non-selective histone deacetylase inhibitor. Panobinostat is commercially available in the form of a capsule-type oral agent under the trade name Farydak (registered trademark).
[0003] On the other hand, liposomal preparations have been widely studied to accumulate drugs in cancer cells and expose them to the tumor for a long period of time. Liposomal preparations are preparations in which drugs are encapsulated in liposomes made of lipid membranes.
[0004] For example, a liposome preparation targeted to bone marrow is described in Non-Patent Document 1. Non-Patent Document 1 describes a liposome containing 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), cholesterol, L-glutamic acid, N-(3-carboxyl-1-oxopropyl)-1,5-dihexadecyl ester (SA lipid), and poly(ethylene glycol), and describes that the SA lipid component is an active factor that induces phagocytosis by bone marrow phagocytes.
[0005] Non-Patent Document 2 describes that liposomes (CPX-351) encapsulating cytarabine and daunorubicin exhibit high bone marrow accumulation. Non-Patent Document 2 also describes that the accumulation of CPX-351 in bone marrow is 20% to 50% higher in normal mice than empty liposomes, and 75% higher in leukemia model mice than empty liposomes. [Prior art documents] [Non-patent literature]
[0006] [Non-Patent Document 1] Keitaro Sou et al., Expert Opin Drug Deliv. 2011 March; 8(3): 317-328 [Non-Patent Document 2] Abstract 5534: Liposome accumulation within leukemia engrafted bone marrow is significantly enhanced when the formulation contains cytarabine plus daunorubicin,, Sharon A. Johnstone, Sherwin Xie, Troy Harasym, Lawrence Mayer and Paul G. Tardi, DOI: 10.1158 / 1538-7445.AM10-5534 Published 15 April 2010, Proceedings: AACR 101st Annual Meeting 2010, Apr 17-21, 2010; Washington, DC Summary of the Invention [Problem to be solved by the invention]
[0007] As described above, although there are several reports on liposomes that exhibit high bone marrow accumulation, there is no knowledge of a liposome composition that contains panobinostat or a salt thereof and exhibits high bone marrow targeting ability. An objective of the present invention is to provide a lipid particle composition that contains panobinostat or a salt thereof and exhibits high bone marrow targeting ability, and a pharmaceutical composition that contains the lipid particle composition. [Means for solving the problem]
[0008] Means for Solving the Problems The present inventors conducted intensive research to solve the above-mentioned problems and discovered that a lipid particle composition containing panobinostat or a salt thereof, wherein the lipid particles contain phospholipids and cholesterols, exhibits high targeting ability to bone marrow, thereby completing the present invention.
[0009] That is, the present invention provides the following. [1] A lipid particle composition comprising panobinostat or a salt thereof, wherein the lipid particles comprise phospholipids and cholesterols. [2] A lipid particle composition containing panobinostat or a salt thereof, wherein the area ratio represented by the following formula 1 is 5 or more from a single administration of the lipid particle composition at a panobinostat amount of 4 mg / kg into the tail vein of a mouse to an infinite time. Equation 1: (Area under the bone marrow concentration-time curve) / (Area under the gastrointestinal concentration-time curve) [3] The lipid particle composition according to [1] or [2], wherein the average particle size of the lipid particles is 50 nm to 500 nm. [4] The lipid particle composition according to any one of [1] to [3], wherein panobinostat or a salt thereof is encapsulated in the lipid particle by a remote loading method. [5] The lipid particle composition according to any one of [1] to [4], wherein a solidified form of panobinostat or a salt thereof is present on the surface and at least a portion of the interior of the lipid particle. [6] The lipid particle composition described in any one of [2] to [5], wherein the lipid particle contains phospholipids and cholesterols. [7] The lipid particle composition according to any one of [1] to [6], comprising a phospholipid having a glycerol backbone as the phospholipid. [8] The lipid particle composition according to [7], wherein the phospholipid having a glycerol backbone is phosphatidylcholine. [9] The lipid particle composition according to any one of [1] to [6], comprising a sphingophospholipid as the phospholipid.
[10] The lipid particle composition described in [9], wherein the sphingophospholipid is sphingomyelin.
[11] The lipid particle composition described in any one of [1] to
[10] , wherein the phospholipid contains a fatty acid residue having 20 or more carbon atoms.
[12] The lipid particle composition described in any one of [1] to
[11] , wherein the lipid particle further contains a polyethylene glycol lipid.
[13] The lipid particle composition according to
[12] , wherein the ratio of polyethylene glycol lipid to the total lipids constituting the lipid particle is 5 mol % or less.
[14] The lipid particle composition described in any one of [1] to
[11] , wherein the lipid particle is substantially free of polyethylene glycol lipid.
[15] The lipid particle composition according to any one of [1] to
[14] , wherein the lipid particle contains an anionic lipid.
[16] A pharmaceutical composition comprising the lipid particle composition described in any one of [1] to
[15] .
[17] The pharmaceutical composition described in
[16] , which is an anticancer agent.
[0010]
[18] A method for treating a subject, comprising administering to the subject a lipid particle composition described in any one of [1] to
[17] .
[19] A lipid particle composition described in any one of [1] to
[17] for use in the treatment of cancer.
[20] Use of the lipid particle composition described in any one of [1] to
[17] for the manufacture of a pharmaceutical composition.
[21] Use of the lipid particle composition described in any one of [1] to
[17] for the manufacture of an anticancer agent. Effect of the Invention
[0011] The lipid particle composition and pharmaceutical composition of the present invention exhibit high bone marrow targeting ability. According to the lipid particle composition and pharmaceutical composition of the present invention, it is possible to provide a pharmaceutical composition with an improved therapeutic index. [Brief description of the drawings]
[0012] [Figure 1]FIG. 1 shows images of panobinostat-containing lipid particles taken by a Transmission Electron Microscope (TEM). [Diagram 2] FIG. 2 shows the results of measurements of panobinostat concentrations in plasma following administration of panobinostat-containing lipid particles or a panobinostat solution. [Diagram 3] FIG. 3 shows the results of measuring panobinostat concentrations in tissues following administration of panobinostat-containing lipid particles or a panobinostat solution. [Figure 4] FIG. 4 shows the results of measuring the growth inhibitory activity against leukemia cells in Molm-13 orthotopic model mice. [Diagram 5] FIG. 5 shows the results of analyzing the number of bone marrow macrophages and the amount of lipid particles in cells. [Figure 6] FIG. 6 shows the results of analyzing the expression of cytokines in the bone marrow. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0013] In this specification, a numerical range indicated using "~" indicates a range that includes the numerical values before and after "~" as the minimum and maximum values, respectively. In this specification, the amount of each component in a composition means the total amount of the multiple substances present in the composition when multiple substances corresponding to each component are present in the composition, unless otherwise specified.
[0014] "Empty liposome" means a liposome that does not contain a drug. "Release" means that a drug contained in a lipid particle (such as a liposome) passes through the lipid membrane that constitutes the lipid particle (such as a liposome) and goes out of the lipid particle (such as a liposome). "Blood retention" refers to the property of a drug encapsulated in lipid particles (such as liposomes) being present in the blood of a subject to whom a lipid particle (such as liposome) composition has been administered.
[0015] "Average particle size of lipid particles (e.g., liposomes)" refers to the volume average particle size of lipid particles (e.g., liposomes) present in a lipid particle (e.g., liposome) composition. The average particle size of lipid particles contained in the lipid particle composition of the present invention is measured using a dynamic light scattering method. Commercially available measuring devices using dynamic light scattering include the concentrated particle analyzer FPAR-1000 (manufactured by Otsuka Electronics Co., Ltd.), Nanotrack UPA (manufactured by Nikkiso Co., Ltd.), and Nanosizer (manufactured by Malvern Instruments).
[0016] The "subject" refers to a mammal such as a human, mouse, monkey, livestock, etc., who is in need of prevention or treatment of a disease or the like, and is preferably a human who is in need of prevention or treatment of a disease or the like.
[0017] The present invention will be described in detail below. The lipid particle composition of the present invention is a lipid particle composition containing panobinostat or a salt thereof, wherein the lipid particles contain phospholipids and cholesterols.
[0018] (lipid particles) The lipid particles refer to particles composed of lipids, and are not particularly limited. The lipid particles of the present invention include liposomes having a lamellar structure, which is a closed vesicle composed of a lipid bilayer membrane. A liposome is a closed vesicle formed of a lipid bilayer membrane using lipids, and has an aqueous phase (internal aqueous phase) in the space of the closed vesicle. The internal aqueous phase includes water and the like. Liposomes usually exist in a dispersed state in an aqueous solution (external aqueous phase) outside the closed vesicle. Liposomes may be single-lamellar (also called unilamellar or unilamellar, with a single bilayer membrane structure) or multi-lamellar (also called multi-lamellar, with a structure of multiple bilayer membranes in an onion-like shape. Each layer is separated by a water-like layer), but in the present invention, single-lamellar liposomes are preferred from the viewpoint of safety and stability in medical applications.
[0019] The lipid particles of the present invention also include particles that do not have a lipid bilayer structure (lamellar structure) like the above-mentioned liposomes, and have a structure in which the interior of the particle is packed with constituent components. The morphology of lipid formation can be confirmed by electron microscopy or structural analysis using X-rays. For example, by using a cryo-transmission electron microscope (CryoTEM) method, it can be confirmed that the lipid particles have a structure with a lipid bilayer structure (lamellar structure) and an inner water layer, like liposomes, or that the lipid particles have a structure packed with lipids and other components, such as liposomes, without a lipid bilayer structure (lamellar structure) and an inner water layer and with a core with high electron density inside the particle. Small angle X-ray scattering (SAXS) measurements can also be used to confirm whether the lipid particles have a lipid bilayer structure (lamellar structure).
[0020] The lipid particles are not particularly limited in form as long as they are lipid particles that can encapsulate a drug. "Encapsulation" means that the lipid particles are in a form in which the drug is contained in the internal aqueous phase and / or the membrane itself. For example, the form in which the drug is enclosed in a closed space formed by the membrane, the form in which the drug is encapsulated in the membrane itself, etc., and combinations thereof are also acceptable.
[0021] The average particle size of the lipid particles is generally 10 nm to 1000 nm, preferably 50 nm to 500 nm, more preferably 100 nm to 500 nm, and even more preferably 100 nm to 300 nm. The lipid particles preferably have a spherical or nearly spherical shape.
[0022] The zeta potential of the lipid particles of the present invention is not particularly limited, but is preferably -10 mV or less, more preferably -15 mV or less, even more preferably -20 mV or less, also preferably -25 mV or less, and even more preferably -30 mV or less.
[0023] The components constituting the lipid bilayer of the lipid particles are selected from lipids. Any lipid that dissolves in a mixed solvent of a water-soluble organic solvent and an ester-based organic solvent can be used. Examples of lipids include phospholipids, lipids other than phospholipids, cholesterols, lysophospholipids and their derivatives. These components may be composed of a single type or multiple types of components. The lipid particles of the present invention contain at least phospholipids and cholesterols.
[0024] Examples of phospholipids include natural or synthetic phospholipids such as phosphatidylcholine (lecithin), phosphatidylglycerol, phosphatidic acid, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, dihydrosphingomyelin, cardiolipin, etc., and hydrogenated versions of these phospholipids (e.g., hydrogenated soybean phosphatidylcholine (HSPC)). In the present invention, the term "phospholipid" also includes phospholipid derivatives obtained by modifying phospholipids.
[0025] In the present invention, the phospholipid preferably contains a phospholipid having a glycerol backbone. As the phospholipid having a glycerol backbone, phosphatidylcholine is particularly preferable. As the phosphatidylcholine, 1,2-diarachidonoyl-sn-glycero-3-phosphocholine or the like can be used. In addition, in the present invention, it is also preferable that the phospholipid contains a sphingophospholipid. As the sphingophospholipid, sphingomyelin or the like can be used.
[0026] The phospholipid in the present invention preferably contains a fatty acid residue having 20 or more carbon atoms, from the viewpoint of reducing the release of panobinostat or a salt thereof and improving retention in blood.
[0027] Examples of lipids other than phospholipids include lipids that do not contain phosphoric acid, such as glycerolipids that do not have a phosphoric acid moiety in their molecule, sphingolipids that do not have a phosphoric acid moiety in their molecule, etc. In the present invention, the term "lipids other than phospholipids" also includes derivatives of lipids other than phospholipids that have been modified.
[0028] Cholesterols include cholesterol and its derivatives, which have a cyclopentahydrophenanthrene skeleton with some or all of the carbon atoms hydrogenated. For example, cholesterol can be mentioned. When the average particle size of lipid particles is reduced to 100 nm or less, the curvature of the lipid membrane increases. The distortion of the membrane arranged in the lipid particles also increases. In order to fill the membrane distortion caused by lipids (membrane stabilization effect), it is effective to add cholesterol, etc.
[0029] In lipid particles, the addition of cholesterol is expected to reduce the fluidity of the lipid particle membrane by, for example, filling gaps in the lipid particle membrane.
[0030] The content of cholesterols relative to the total amount of lipids constituting the lipid particles according to the present invention is preferably 10 mol % to 50 mol %, more preferably 20 mol % to 45 mol %, further preferably 30 mol % to 45 mol %, and particularly preferably 35 mol % to 45 mol %.
[0031] The lipid particles of the present invention may contain a lipid modified with a hydrophilic polymer. Examples of hydrophilic polymers include polyethylene glycols, polyglycerins, polypropylene glycols, polyvinyl alcohol, styrene-maleic anhydride alternating copolymers, polyvinylpyrrolidone, synthetic polyamino acids, etc. The above hydrophilic polymers can be used alone or in combination of two or more kinds.
[0032] Among these, from the viewpoint of blood retention of the composition, polyethylene glycols, polyglycerols and polypropylene glycols are preferred, and polyethylene glycol (PEG), polyglycerol (PG) and polypropylene glycol (PPG) are more preferred. From the viewpoint of versatility and blood retention, polyethylene glycol (PEG) is even more preferred.
[0033] The weight average molecular weight of the polyethylene glycol is not particularly limited, but is generally 500 to 10,000 daltons, preferably 1,000 to 7,000 daltons, and more preferably 2,000 to 5,000 daltons.
[0034] In the first embodiment of the lipid particles of the present invention, it is preferable to use a lipid modified by PEG (polyethylene glycol lipid) together with the main lipid contained in the lipid particles. Examples of the polyethylene glycol lipid include 1,2-distearoyl-3-phosphatidylethanolamine-PEG2000 (manufactured by NOF Corporation), 1,2-distearoyl-3-phosphatidylethanolamine-PEG5000 (manufactured by NOF Corporation), and distearoylglycerol-PEG2000 (manufactured by NOF Corporation), and other 1,2-distearoyl-3-phosphatidylethanolamine-polyethylene glycols.
[0035] The ratio of polyethylene glycol lipid to the total lipids constituting the lipid particles is generally 0.01 to 10 mol%, preferably 0.05 to 8 mol%, more preferably 0.1 to 7 mol%, also preferably 5 mol% or less, and even more preferably 1 mol% or less.
[0036] As a second form of lipid particle in the present invention, it is preferable that the lipid particle is substantially free of polyethylene glycol lipid.
[0037] The lipid particles of the present invention preferably contain an anionic lipid in addition to the main lipid contained in the lipid particles. Examples of anionic lipids include lipids having phosphatidylglycerol such as 1,2-Dipalmitoyl-sn-glycero-3-phosphoglycerol, sodium salt (COATSOME MG-6060LS, manufactured by NOF Corp.), lipids having phosphatidic acid such as 1,2-Dimyristoyl-sn-glycero-3-phosphatidic acid, sodium salt (COATSOME MA-6060LS, manufactured by NOF Corp.), lipids having phosphatidylserine such as 1,2-Dipalmitoyl-sn-glycero-3-phospho-L-serine, sodium salt (COATSOME MS-6060LS, manufactured by NOF Corp.), lysophospholipids such as 1-Stearoyl-2-lyso-sn-glycero-3-phosphocholine (COTSOME MC-80H, manufactured by NOF Corp.), and cholesterol hemisuccinate (CHEMS, Avanti Polar). Examples of suitable steroid derivatives include those having an anionic group such as steroid derivatives having an anionic group, ...
[0038] The ratio of anionic lipid in the total lipid constituting the lipid particle is not particularly limited, but is 0.01 to 50 mol%, preferably 0.05 to 30 mol%, more preferably 0.1 to 10 mol%. The anionic lipid may be used in combination with PEG lipid, or may be used alone without PEG lipid. The above hydrophilic polymers may be used alone or in combination of two or more kinds.
[0039] In addition to the above components, the lipid particles may contain hydrophilic polymers to improve blood retention, fatty acids or diacetyl phosphate as membrane structure stabilizers, and α-tocopherol as antioxidants. In the present invention, it is preferable not to use additives such as dispersion aids that are not approved for use in intravenous injection in medical applications, for example, surfactants.
[0040] (Panobinostat) The lipid particle composition of the present invention contains panobinostat or a salt thereof as a drug. Panobinostat is a hydroxamic acid derivative used in the treatment of multiple myeloma and is a nonselective histone deacetylase inhibitor. The chemical structure of panobinostat is shown below.
[0041] [ka]
[0042] Examples of salts of panobinostat include commonly known salts of a basic group such as an amino group. Examples of salts at basic groups include salts with mineral acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, boric acid, nitric acid, and sulfuric acid; salts with organic carboxylic acids such as formic acid, acetic acid, lactic acid, citric acid, oxalic acid, fumaric acid, maleic acid, succinic acid, malic acid, tartaric acid, aspartic acid, trichloroacetic acid, and trifluoroacetic acid; and salts with sulfonic acids such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, mesitylenesulfonic acid, and naphthalenesulfonic acid. An example of a salt of panobinostat is the lactate salt of panobinostat, the structure of which is shown below.
[0043] [ka]
[0044] (Panobinostat or a salt thereof contained in lipid particle composition) In the lipid particle composition of the present invention, the state in which panobinostat or a salt thereof is present in the lipid particles is not particularly limited, but as described below, due to the difference in accumulation in bone marrow compared to empty liposomes, it is presumed that at least a portion of panobinostat or a salt thereof is present in a form that affects recognition by blood proteins or cells such as macrophages that recognize lipid particles. In other words, it is presumed that a portion of panobinostat or a salt thereof is present on the membrane surface of the lipid particle, or in a state that affects the motility of lipid molecules present on the membrane surface.
[0045] In the lipid particle composition of the present invention, when the encapsulated panobinostat or its salt is at a high concentration, as can be seen from the TEM image in FIG. 1, the state of existence of panobinostat or its salt may be such that a part of panobinostat or its salt is present as a solidified substance on at least a part of the surface and inside of the lipid particle. Even in such a case, the remainder of panobinostat or its salt may be present in a dissolved state in the internal aqueous phase of the lipid particle. Here, the dissolved state refers to a state in which the amount of drug filled relative to the volume of the lipid particle is equal to or less than the saturation solubility of the drug in the composition liquid of the internal aqueous phase. In addition, even if the amount is equal to or more than the saturation solubility, if no drug crystals are observed in Cryo-TEM [observation of frozen samples with a transmission electron microscope (TEM)] or no diffraction pattern due to crystal lattice is observed in XRD measurement, it can be considered that most of the drug encapsulated in the lipid particle is dissolved and present in a dissolved state.
[0046] In the present invention, the solidified material means a solid that can be observed with a transmission electron microscope (TEM).
[0047] (Panobinostat or its salt / lipid ratio) The ratio of panobinostat or its salt / lipid in the lipid particles of the present invention is 10-500 mg / mmol, preferably 20-400 mg / mmol, more preferably 30-300 mg / mmol. When a salt of panobinostat is contained, the panobinostat or its salt / lipid ratio is calculated based on the amount of panobinostat. Note that the lipid in the panobinostat or its salt / lipid ratio means all lipids constituting the lipid particles, and lipids include cholesterol and lysophospholipids.
[0048] (Lipid particle composition) In the lipid particle composition of the present invention, the area ratio represented by the following formula 1 from a single administration of 4 mg / kg of the lipid particle composition in terms of panobinostat into the tail vein of a mouse to infinite time is preferably greater than 1, more preferably 2 or more, even more preferably 3 or more, even more preferably 5 or more, even more preferably 10 or more, and particularly preferably 12 or more. Equation 1: (Area under the bone marrow concentration-time curve) / (Area under the gastrointestinal concentration-time curve)
[0049] In the lipid particle composition of the present invention, the bone marrow accumulation rate (% ID / g) shown by the following formula 2 is preferably 10% ID / g or more, more preferably 15% ID / g or more, more preferably 20% ID / g or more, even more preferably 30% ID / g or more, and particularly preferably 40% ID / g or more. The bone marrow accumulation rate shown in the examples of the present invention was calculated as the ratio of lipid particles accumulated in the bone marrow (% injected dose / g) per 1 g of femoral bone marrow 72 hours after administration of a panobinostat-containing lipid particle composition (6 mg / kg or 4 mg / kg as panobinostat) labeled with DiI (1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate) into the tail vein of a mouse, and is shown by the following formula 2. Formula 2: Bone marrow accumulation rate (%ID / g) = DiI concentration in bone marrow (ng / g) / (DiI concentration in administration solution (ng / mL) × administration volume (mL)) × 100
[0050] To determine the bone marrow accumulation rate (%ID / g), a label other than DiI used in the present invention may be used, or the bone marrow accumulation rate may be determined by tracing the lipids constituting the lipid particles without using a label. In addition to the method of labeling the lipid particle composition beforehand as shown in the examples of the present invention, the bone marrow accumulation rate can also be determined by using a method of labeling the lipid particle composition afterwards as shown in Example 25.
[0051] The lipid particle composition of the present invention can comprise lipid particles containing panobinostat or a salt thereof, and an aqueous solvent in which the lipid particles are dispersed.
[0052] The lipid particle composition of the present invention may contain at least one of pharma-ceutically acceptable tonicity agents, stabilizers, antioxidants, and pH adjusters, depending on the route of administration.
[0053] Examples of isotonicity agents include, but are not limited to, inorganic salts such as sodium chloride, potassium chloride, sodium hydrogen phosphate, sodium dihydrogen phosphate, and potassium dihydrogen phosphate; polyols such as glycerol, mannitol, and sorbitol; and sugars such as glucose, fructose, lactose, or sucrose.
[0054] Stabilizers include, but are not limited to, sugars such as glycerol, mannitol, sorbitol, lactose, or sulose.
[0055] The antioxidant is not particularly limited, but examples thereof include ascorbic acid, uric acid, tocopherol homologues (e.g., vitamin E, and the four isomers of tocopherol α, β, γ, and δ), cysteine, EDTA (ethylenediaminetetraacetic acid), propyl gallate, BHT (dibutylhydroxytoluene), BHA (butylhydroxyanisole), sodium pyrosulfite, etc. The stabilizers and antioxidants can each be used alone or in combination of two or more kinds.
[0056] Examples of the pH adjuster include sodium hydroxide, citric acid, acetic acid, triethanolamine, sodium hydrogen phosphate, sodium dihydrogen phosphate, and potassium dihydrogen phosphate.
[0057] The lipid particle composition of the present invention may contain pharma- ceutically acceptable organic solvents, collagen, polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymers, sodium carboxymethylcellulose, sodium polyacrylate, sodium alginate, water-soluble dextran, sodium carboxymethylstarch, pectin, methylcellulose, ethylcellulose, xanthan gum, gum arabic, casein, gelatin, agar, diglycerin, propylene glycol, polyethylene glycol, petrolatum, paraffin, stearyl alcohol, stearic acid, human serum albumin (HSA), mannitol, sorbitol, lactose, phosphate buffered saline (PBS), sodium chloride, sugars, biodegradable polymers, serum-free media, and additives acceptable as pharmaceutical additives.
[0058] The container for filling the lipid particle composition of the present invention is not particularly limited, but is preferably made of a material with low oxygen permeability. Examples of the container include a plastic container, a glass container, an aluminum foil, an aluminum vapor deposition film, an aluminum oxide vapor deposition film, a silicon oxide vapor deposition film, a laminate film bag having a gas barrier layer such as polyvinyl alcohol, an ethylene-vinyl alcohol copolymer, polyethylene terephthalate, polyethylene naphthalate, or polyvinylidene chloride, and the like. If necessary, a light-shielding bag using colored glass, aluminum foil, or an aluminum vapor deposition film can be used.
[0059] In order to prevent oxidation due to oxygen present in the space of the container in the container in which the lipid particle composition is filled, it is preferable to replace the gas in the space of the container and in the drug solution with an inert gas such as nitrogen. For example, the injection solution may be bubbled with nitrogen and filled into the container under a nitrogen atmosphere.
[0060] In order to prevent the decomposition of lipids and active pharmaceutical ingredients in the lipid particle composition, it is also preferable to perform freeze-drying. For example, lipid particles are dispersed in an aqueous phase containing sucrose, and then freeze-drying is performed.
[0061] (Method of producing lipid particle composition) The method for producing the lipid particle composition of the present invention is not particularly limited, but an example thereof is (a) Preparation of the oil phase; (b) Preparation of the aqueous phase; (c) lipid particle formation by emulsification; (d) Granulation using an extruder; (e) Replacement of the aqueous phase outside the lipid particles by dialysis; (f) encapsulation of panobinostat into lipid particles by remote loading; and (g) Removal of external aqueous phase panobinostat by dialysis: It can be manufactured by the following process.
[0062] <(a) Preparation of oil phase> (a) In preparing the oil phase, the components constituting the lipid particles (phospholipids, cholesterols, etc.) are mixed with an organic solvent, and the mixture is heated to dissolve the above components, thereby producing the oil phase. The organic solvent used in the oil phase is not particularly limited, but for example, a water-soluble organic solvent that is arbitrarily miscible with water can be used.
[0063] Examples of the water-soluble organic solvent include alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, and t-butanol, glycols such as glycerin, ethylene glycol, and propylene glycol, and polyalkylene glycols such as polyethylene glycol. Among these, alcohols are preferred. The alcohol is preferably at least one selected from ethanol, methanol, 2-propanol, and t-butanol, more preferably at least one selected from ethanol, 2-propanol, and t-butanol, and even more preferably ethanol.
[0064] The lipid concentration is not particularly limited and can be adjusted appropriately.
[0065] <(b) Preparation of aqueous phase> As the aqueous phase, water (distilled water, water for injection, etc.), physiological saline, various buffer solutions or aqueous solutions of sugars, and mixtures thereof (aqueous solvents) can be used. In the present invention, when panobinostat is encapsulated in lipid particles by remote loading, which will be described later, it is preferable to use an aqueous solution containing an ammonium salt as the aqueous phase.
[0066] The buffer solution is not limited to organic or inorganic, but a buffer solution having a buffering effect near the hydrogen ion concentration close to that of body fluids is preferably used, such as phosphate buffer, Tris buffer, citrate buffer, acetate buffer, and Good's buffer. The inner aqueous phase of the lipid particles may be an aqueous solution in which the lipid particles are dispersed when the lipid particles are produced, or may be newly added water, physiological saline, various buffers, or aqueous solutions of sugars, or mixtures thereof. The water used as the outer aqueous phase or inner aqueous phase preferably does not contain impurities (dust, chemicals, etc.).
[0067] Physiological saline refers to an inorganic salt solution adjusted to be isotonic with the human body and may further have a buffer function. Examples of physiological saline include saline containing 0.9 w / v% (mass / volume percent) sodium chloride, PBS, and Tris-buffered saline.
[0068] In the present invention, the aqueous phase includes both the external aqueous phase and the internal aqueous phase. The external aqueous phase in the present invention means the aqueous solution that disperses lipid particles.For example, in the case of injection, the solution that occupies the outside of lipid particles in the lipid particle dispersion liquid that is packaged and stored in a vial or prefilled syringe is the external aqueous phase.In addition, in the case of the liquid that is dispersed at the time of administration by the attached dispersion liquid or other dissolving liquid, the solution that occupies the outside of lipid particles in the lipid particle dispersion liquid is the external aqueous phase. In the present invention, the internal aqueous phase means the aqueous phase within closed vesicles separated by the lipid bilayer membrane of the lipid particle.
[0069] <(c) Formation of lipid particles by emulsification> In the emulsification process, an oil phase in which at least one type of lipid is dissolved in an organic solvent and an aqueous phase are mixed, and the lipid-containing aqueous solution is stirred and emulsified. By mixing, stirring, and emulsifying the oil phase in which lipids are dissolved in an organic solvent and the aqueous phase, an emulsion in which the oil phase and the aqueous phase are emulsified into an O / W type (oil-in-water type) is prepared. After mixing, lipid particles are formed by removing part or all of the organic solvent from the oil phase by evaporation. Alternatively, lipid particles are formed by evaporating part or all of the organic solvent in the oil phase during the stirring and emulsification process.
[0070] As a method of stirring, ultrasonic waves or mechanical shearing force are used to make the particles finer. In addition, to make the particle size uniform, an extruder treatment or a microfluidizer treatment can be performed to pass the particles through a filter with a certain pore size. By using an extruder or the like, the multivesicular lipid particles formed secondarily can be broken down into single-vesicular lipid particles.
[0071] The emulsification step is not limited as long as it is an emulsification step, but is preferably a step of forming fine particles by applying high shear and emulsifying the lipid particles using an organic solvent. If necessary, the organic solvent used in the emulsification step can be evaporated (desolvated) to form lipid particles.
[0072] The liquid temperature in the emulsification step in producing lipid particles can be adjusted as appropriate, but it is preferable that the liquid temperature when mixing the oil phase and the aqueous phase is equal to or higher than the phase transition temperature of the lipid used. For example, when a lipid with a phase transition temperature of 35 to 40°C is used, the liquid temperature is preferably 35°C to 70°C.
[0073] In the emulsification process, the organic solvent and water may be evaporated from the aqueous solution containing the lipid particles. The evaporation referred to here may be a forced removal of part or all of the organic solvent derived from the oil phase and the water derived from the aqueous phase in an evaporation process, or a natural evaporation of part or all of the organic solvent derived from the oil phase and the water derived from the aqueous phase during the stirring and emulsification process.
[0074] The evaporation method is not particularly limited, but may be, for example, at least one of a step of evaporating the organic solvent and water by heating, a step of allowing the mixture to stand or continue gentle stirring after emulsification, and a step of vacuum degassing.
[0075] <(d) Particle size regulation using an extruder> The particle size of the obtained lipid particles can be made uniform by dialysis, filtration, extrusion treatment or the like. The extrusion process refers to a process of passing lipid particles through a filter having fine holes, thereby applying physical shearing force to the lipid particles, thereby atomizing the lipid particles. When passing the lipid particles through the filter, the lipid particle dispersion and the filter are kept at a temperature equal to or higher than the phase transition temperature of the membrane constituting the lipid particles, thereby enabling the lipid particles to be rapidly atomized. Incidentally, particle size regulation using an extruder may or may not be performed.
[0076] <(e) Replacement of the aqueous phase outside lipid particles by dialysis> In the present invention, when panobinostat is encapsulated in lipid particles by remote loading, the lipid particle external aqueous phase liquid may be replaced by dialysis. As the dialysis liquid, a 0.1 to 5 mass% NaCl aqueous solution can be used, but is not particularly limited. By dialyzing the lipid particle liquid using the above-mentioned dialysis liquid, the ammonium salt present in the external aqueous phase can be removed, and lipid particles in which the external aqueous phase is replaced with the dialysis liquid can be obtained.
[0077] <(f) Encapsulation of panobinostat into lipid particles by remote loading method> In the present invention, it is preferable to encapsulate panobinostat in lipid particles by a remote loading method.
[0078] In the present invention, the remote loading method refers to a method in which empty liposomes containing no drug are prepared, and the drug is added to the liposome external solution to introduce the drug into the liposome. The remote loading method is not particularly limited, but examples thereof include methods using a citrate buffer solution or ammonium sulfate.
[0079] In the remote loading method, drugs added to the external solution actively migrate into the lipid particles and are taken up by the lipid particles. The driving force used is the solubility gradient, ion gradient, pH gradient, etc. For example, there is a method of introducing drugs into the lipid particles using the ion gradient formed across the lipid particle membrane. For example, Na + / K + There is a technique for adding a drug to lipid particles that have been formed in advance by a remote loading method, utilizing a concentration gradient.
[0080] Among ion gradients, a proton concentration gradient is generally used, for example, a pH gradient in which the pH inside (internal aqueous phase) of the lipid particle membrane is lower than the pH outside (external aqueous phase) using citric acid.Specifically, the pH gradient can be formed by an ammonium ion gradient and / or a concentration gradient of an organic compound having a protonizable amino group.
[0081] The ammonium ion source is not particularly limited, but a water-soluble ammonium salt is preferably used, and examples thereof include ammonium sulfate, ammonium chloride, ammonium formate, ammonium succinate, and ammonium acetate.
[0082] <(g) Removal of external aqueous phase panobinostat by dialysis> The lipid particle liquid encapsulating panobinostat may be dialyzed to remove panobinostat that is not included in the lipid particles. For example, the lipid particle liquid encapsulating panobinostat can be dialyzed using a sucrose / histidine buffer of a predetermined concentration as a dialysis solution to remove panobinostat present in the external aqueous phase, thereby obtaining a lipid particle composition in which the external aqueous phase is replaced with the dialysis solution.
[0083] <Sterile filtration> The lipid particle composition obtained above is preferably subjected to sterile filtration. As a filtration method, unnecessary substances can be removed from the aqueous solution containing lipid particles using a hollow fiber membrane, a reverse osmosis membrane, a membrane filter, or the like. In the present invention, filtration is preferably performed using a filter having a pore size that can be sterilized (preferably a 0.2 μm filtration sterilization filter).
[0084] In order to prevent the average particle size from being affected by deformation of the lipid particles, the sterile filtration step and the sterile filling step described below are preferably carried out at a temperature equal to or lower than the phase transition temperature of the lipid constituting the lipid particles. For example, when the phase transition temperature of the lipid is around 50°C, the production temperature is preferably about 0 to 40°C, more specifically, about 5 to 30°C.
[0085] <Aseptic filling> The lipid particle composition obtained after the sterile filtration is preferably aseptically filled for medical use. A known method for aseptic filling can be applied. By aseptically filling the container, a lipid particle composition suitable for medical use can be prepared.
[0086] Pharmaceutical Composition The lipid particle composition of the present invention can be used as a pharmaceutical composition. That is, according to the present invention, there is provided a pharmaceutical composition comprising the lipid particle composition of the present invention.
[0087] The administration route of the pharmaceutical composition of the present invention is preferably parenteral administration.For example, it can include intravenous injection (intravenous injection) such as drip infusion, intramuscular injection, intraperitoneal injection, subcutaneous injection, intraocular injection and intrathecal injection.The administration method can include administration by syringe or drip infusion.
[0088] The dosage and frequency of administration of panobinostat or a salt thereof as a drug contained in the lipid particle composition can generally be set within the range of 0.01 mg / kg to 100 mg / kg per day in terms of the mass of panobinostat or a salt thereof, but the lipid particle composition of the present invention is not limited to these dosages.
[0089] The pharmaceutical composition of the present invention can be preferably used as an anticancer agent. The type of cancer to which the pharmaceutical composition of the present invention can be applied is not particularly limited, but examples include multiple myeloma, acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, adult T-cell leukemia, bone marrow metastatic cancer, osteosarcoma, chronic myelomonocytic leukemia, Hodgkin's lymphoma, cutaneous T-cell lymphoma, breast cancer, prostate cancer, uterine cancer, ovarian cancer, lung cancer, gastric (gastric adenocarcinoma), non-small cell lung cancer, pancreatic cancer, cervical squamous cell carcinoma, esophageal cancer, bladder cancer, melanoma, colon cancer, renal cell carcinoma, non-Hodgkin's lymphoma, and urothelial cancer. EXAMPLES
[0090] The present invention will be described in detail below with reference to examples, but the present invention is not limited to these examples.
[0091] [Preparation of lipid particle composition] <Example 1> (a) Preparation of oil phase 1,2-diarachidonoyl-sn-glycero-3-phosphocholine (manufactured by Nippon Fine Chemicals, hereafter referred to as C20PC), PEG phospholipid (SUNBRIGHT DSPE-020CN, manufactured by NOF Corp., hereafter referred to as DSPE-PEG), and cholesterol were weighed out at 0.495 g, 0.153 g, and 0.153 g, respectively. To label the lipid particles with DiI (1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine Perchlorate), an amount of DiI equivalent to 0.2 mol% of the total lipid was weighed and dissolved in ethanol. Ethanol was added to this DiI ethanol solution to make the total volume 11.25 mL, and 3.75 mL of ethyl acetate was further added. The weighed lipid and this organic solvent were mixed and heated to 60°C to dissolve the lipid and form an oil phase.
[0092] (b) Preparation of the aqueous phase An aqueous phase was prepared by dissolving 0.9 g of ammonium sulfate in 40 g of water.
[0093] (c) Formation of lipid particles by emulsification The aqueous phase prepared in (b) was heated to 70°C, and the entire amount of the oil phase prepared in (a) was added (volume ratio: aqueous phase / oil phase = 8 / 3). The mixture was then mixed in an emulsifier (Excel Auto Homogenizer ED-3, manufactured by Nippon Seiki Seisakusho) at 3000 rpm (rotation per minute: 1 / 60 s). -1 ) for 30 minutes. Next, the organic solvent and water were evaporated by continuing to stir at 300 rpm while heating at 65°C, and when the liquid was concentrated to 15 g, heating and stirring were stopped to stop evaporation.
[0094] (d) Particle size regulation using an extruder In Example 1, no sizing was performed, but in the Examples shown in the table below, in those in which the filter size is listed in the "sizing" column, sizing was performed as follows. Sizing was performed by passing the liquid obtained in (c) through filters in sequence using an extruder (Mini Extruder, manufactured by Avanti Polar Lipids) under heating at 70°C. The filter sizes used were those listed in the "sizing" column of each table. In Examples in which multiple filter sizes are listed, sizing was performed using a filter with a large pore size, followed by sizing using a filter with a small pore size.
[0095] (e) Replacement of the aqueous phase outside the lipid particles by dialysis A 2.43% by mass aqueous NaCl solution was used as the dialysis solution. The solution obtained in (c) or (d) was dialyzed at room temperature using this dialysis solution to remove ammonium sulfate present in the external aqueous phase and obtain lipid particles in which the external aqueous phase was replaced with the dialysis solution.
[0096] (f) Encapsulation of panobinostat into lipid particles by remote loading Panobinostat (manufactured by APAC PHARMACEUTICAL, LLC) was mixed with water for injection to make it 10 mg / mL. Furthermore, 8 mol / L HCl solution was added while stirring the liquid well to adjust the pH to about 3 to dissolve panobinostat. Lipid particles were added to this panobinostat solution in a volume ratio of 1 / 1, and then the mixture was heated at 60°C for 120 minutes.
[0097] (g) Removal of external aqueous phase panobinostat by dialysis A sucrose / histidine buffer consisting of 9.4% by mass sucrose and 10 mmol / L histidine was prepared as the dialysis solution. The solution obtained in (f) was dialyzed at room temperature using this dialysis solution to remove panobinostat present in the external aqueous phase, and panobinostat-containing lipid particles in which the external aqueous phase was replaced with the dialysis solution were obtained.
[0098] <Example 2> Panobinostat-containing lipid particles were obtained in the same manner as in Example 1, except that the amount of DSPE-PEG used was 0.0153 g.
[0099] <Examples 3 to 13> Panobinostat-containing lipid particles were obtained in the same manner as in Example 1, except that the lipid composition was as shown in the table below. In the table below, SM stands for sphingomyelin (COATSOME NM-10, manufactured by NOF Corp.), and DHSM stands for dihydrosphingomyelin (a synthetic product obtained by hydrogenating COATSOME NM-10 (manufactured by NOF Corp.)).
[0100] <Example 14> (a) Preparation of oil phase Sphingomyelin (COATSOME NM-10, NOF Corp., hereafter referred to as SM), PEG phospholipid (SUNBRIGHT DSPE-020CN, NOF Corp., hereafter referred to as DSPE-PEG), and cholesterol were weighed out in amounts of 0.420 g, 0.014 g, and 0.155 g, respectively. To label the lipid particles with DiI (1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine Perchlorate), an amount of DiI equivalent to 0.2 mol% of the total lipid was weighed and dissolved in ethanol. Ethanol was added to this DiI ethanol solution to make the total volume 11.25 mL, and 3.75 mL of ethyl acetate was further added. The weighed lipid and this organic solvent were mixed and heated to 70°C to dissolve the lipid and form an oil phase.
[0101] (b) Preparation of the aqueous phase An aqueous phase was prepared by dissolving 0.9 g of ammonium sulfate in 40 g of water.
[0102] (c) Formation of lipid particles by emulsification The aqueous phase prepared in (b) was heated to 70°C and stirred with a magnetic stirrer, and the entire amount of the oil phase prepared in (a) was added thereto and stirred for 30 seconds (volume ratio: aqueous phase / oil phase = 8 / 3). Next, the organic solvent and water were evaporated by continuing stirring at 300 rpm while heating at 65°C, and when the liquid was concentrated to 15 g, heating and stirring were stopped to stop evaporation.
[0103] (d) Particle size regulation using an extruder The liquid obtained in (c) was passed through filters in sequence using an extruder (Mini Extruder, manufactured by Avanti Polar Lipids) while heating at 70°C, and sieving was performed. The filter sizes used were those shown in the "Sizing" column of each table. In examples showing multiple filter sizes, sieving was performed using a filter with a large pore size, followed by sieving using a filter with a small pore size.
[0104] (e) Replacement of the aqueous phase outside the lipid particles by dialysis A 720 mM NaCl aqueous solution was used as the dialysis solution. The solution obtained in (d) was dialyzed at room temperature using this dialysis solution to remove ammonium sulfate present in the external aqueous phase, thereby obtaining lipid particles in which the external aqueous phase was replaced with the dialysis solution.
[0105] (f) Encapsulation of panobinostat into lipid particles by remote loading Panobinostat (manufactured by APAC PHARMACEUTICAL, LLC) was mixed with water for injection to a concentration of 4 mg / mL. In addition, 8 mol / L HCl solution was added while thoroughly stirring the liquid to adjust the pH to about 4 to dissolve panobinostat. This panobinostat solution was mixed with 720 mM NaCl aqueous solution and lipid particles in a volume ratio of 5 / 3 / 2, and then heated at 60°C for 120 minutes.
[0106] (g) Removal of external aqueous phase panobinostat by dialysis A sucrose / histidine buffer consisting of 9.4% by mass sucrose and 10 mmol / L histidine was prepared as the dialysis solution. The solution obtained in (f) was dialyzed at room temperature using this dialysis solution to remove panobinostat present in the external aqueous phase, and panobinostat-containing lipid particles in which the external aqueous phase was replaced with the dialysis solution were obtained.
[0107] <Examples 15 to 25> Panobinostat-containing lipid particles were obtained using the lipid compositions shown in Tables 2 to 4 in the same manner as in Example 14. In Example 25, lipid particles were prepared without adding DiI. In Tables 2 to 4, C20PC represents 1,2-diarachidonoyl-sn-glycero-3-phosphocholine (manufactured by Nippon Fine Chemicals), HSPC represents hydrogenated soybean phosphatidylcholine (COATSOME NC-21, manufactured by NOF Corp.), DPPG represents 1,2-Dipalmitoyl-sn-glycero-3-phosphoglycerol, sodium salt (COATSOME MG-6060LS, manufactured by NOF Corp.), DPPA represents 1,2-Dimyristoyl-sn-glycero-3-phosphatidic acid, sodium salt (COATSOME MA-6060LS, manufactured by NOF Corp.), and DPPS represents 1,2-Dipalmitoyl-sn-glycero-3-phospho-L-serine, sodium salt (COATSOME MS-6060LS, manufactured by NOF Corp.). (f) In the process of encapsulating panobinostat into lipid particles by remote loading, the panobinostat solution was 3.6 mg / mL in Examples 17 to 25. The mixing ratio of the panobinostat solution, 720 mM NaCl aqueous solution, and lipid particles was 8 / 5 / 5 in Example 16, and 2 / 1 / 1 in Examples 17 to 25.
[0108] Only Example 22 has a larger average particle size of 331 nm. This is because a peak of aggregates was observed around 1 μm in particle size measurement by DLS, and the average particle size was calculated to be large. Example 22 has a small absolute value of zeta potential and small electrostatic phase repulsion between particles. In addition, no material such as DSPE-PEG that prevents particles from coalescing due to steric repulsion is added. Although the bone marrow accumulation rate is high, it can be said that the other Examples are more preferable from the viewpoint of particle stability.
[0109] <Example 25> In Example 25, (a) DiI was not added during preparation of the oil phase, and (g) lipid particles that had been dialyzed with a sucrose / histidine buffer were stained with DiI. 500 μL of lipid particle solution was mixed with 5 μL of 3 mg / mL DiI / ethanol solution and thoroughly stirred, and then the external aqueous phase was replaced with a sucrose / histidine buffer consisting of 9.4 mass% sucrose and 10 mmol / L histidine by gel filtration (PD MiniTrap G-25, GE Healthcare) to remove excess DiI.
[0110] <Comparative Example 1> Panobinostat was dissolved in a 1:4 volumetric mixture of polyoxyl 35 castor oil (Kolliphore EL, SIGMA) and polyethylene glycol 400 (Wako Pure Chemical Industries, Ltd.) under ultrasonic irradiation. The resulting solution was mixed with saline in a volumetric ratio of 1:7 to obtain a 0.5 mg / mL panobinostat solution.
[0111] <Comparative Example 2> Lipid particles were prepared by steps similar to those of (a) to (e) in Example 1, and the external aqueous phase was then replaced with the same solution as in Example 1 in the same manner as in (g) in Example 1, thereby obtaining lipid particles not containing panobinostat.
[0112] <Comparative Example 3> HSPC, cholesterol, and DSPE-PEG were weighed out in amounts of 16.63 g, 2.04 g, and 4.15 g, respectively, and dissolved in 303.75 mL of ethanol and 101.25 mL of ethyl acetate together with DiI in an amount of 0.2 mol% relative to the total lipid to form an oil phase. 5.6 g of 100 mmol / L sodium dihydrogen phosphate, 37.6 g of 100 mmol / L disodium hydrogen phosphate, and 1037 g of water for injection were mixed to form an aqueous phase. The oil phase was mixed with the aqueous phase, and an empty liposome labeled with DiI was prepared using an emulsification method. The external aqueous phase was replaced by TFF using a 0.09% by mass sodium chloride aqueous solution, and then pemetrexed was encapsulated by a passive loading method. Dialysis was performed with a sucrose / histidine buffer consisting of 9.4% by mass sucrose and 0.155% by mass histidine to obtain lipid particles containing pemetrexed.
[0113] <Comparative Example 4> HSPC, cholesterol, and DSPE-PEG were weighed out in amounts of 12.42 g, 4.14 g, and 4.14 g, respectively, and dissolved in 303.4 mL of ethanol and 101.25 mL of ethyl acetate together with DiI in an amount equivalent to 0.2 mol% of the total lipids to prepare the oil phase. 26.73 g of ammonium sulfate was dissolved in 1080 g of MilliQ water to prepare the aqueous phase. Empty liposomes labeled with DiI containing ammonium sulfate were prepared using the emulsification method. The external aqueous phase was replaced by TFF using 417 mM sodium chloride aqueous solution, and then doxorubicin hydrochloride was encapsulated by the remote loading method. Dialysis was performed with a sucrose / histidine buffer consisting of 9.4 mass% sucrose and 0.155 mass% histidine to obtain lipid particles containing doxorubicin hydrochloride. The composition of the lipid particles was based on the composition described in the package insert for Doxil Injection 20 mg (doxorubicin hydrochloride 2 mg / mL, HSPC 9.58 mg / mL, DSPE-PEG 3.19 mg / mL, cholesterol 3.19 mg / mL). Quantitative analysis revealed that the contents were 2.24 mg / mL doxorubicin hydrochloride, 11.5 mg / mL HSPC, 4.1 mg / mL DSPE-PEG, and 4.2 mg / mL cholesterol.
[0114] [Physical property measurements and evaluation] <Average particle size> In the present invention, the particle size means the cumulant average particle size measured by the dynamic light scattering method. The average particle sizes of the examples and comparative examples described in each table are the cumulant average particle sizes measured by the dynamic light scattering method using a concentrated particle size analyzer FPAR-1000AS (manufactured by Otsuka Electronics Co., Ltd.) equipped with an autosampler. The measurement results are shown in each table.
[0115] <Zeta potential> In the present invention, the zeta potential means the value measured by the laser Doppler method. The zeta potential of the examples described in each table is the value measured by diluting the lipid particle solution 20-fold with a sucrose / histidine buffer consisting of 9.4 mass% sucrose and 10 mmol / L histidine, which is the same as the external aqueous phase, using a zeta potential / particle size measurement system ELSZ-2 (manufactured by Otsuka Electronics Co., Ltd.). The measurement results are shown in each table.
[0116] <API concentration> In the present invention, the API concentration described in each table is the value obtained by measuring the amount of panobinostat (free form) contained in the lipid particles by HPLC (high performance liquid chromatography). Ultraviolet light (UV) at 279 nm was used for the detection of panobinostat.
[0117] <Lipid concentration> In the present invention, the lipid concentration described in each table is the sum of the concentrations of each lipid quantified by HPLC (high performance liquid chromatography) for each lipid contained in the lipid particles. A corona charged aerosol detector (Corona CAD) was used for the detection of lipids.
[0118] <Observation by transmission electron microscope (TEM)> The lipid particle composition of Example 1 was rapidly frozen and observed under cryo conditions using a general-purpose TEM to obtain a TEM image. The obtained TEM image is shown in FIG. 1. It can be seen from the TEM image of FIG. 1 that the solidified product of panobinostat is present in at least a part of the surface and inside of the lipid particles.
[0119] <Measurement of lipid particle accumulation rate in bone marrow> ICR mice (male, 7 weeks old, ICR stands for Institute of Cancer Research) were used in the test. The panobinostat-containing lipid particles (6 mg / kg as a drug amount) prepared in Examples 1 and 3 to 7 labeled with a fluorescent dye (DiI) were administered via the tail vein. The panobinostat-containing lipid particles (4 mg / kg as a drug amount) prepared in Examples 2 and 8 to 13 labeled with a fluorescent dye (DiI) were administered via the tail vein. The panobinostat-free lipid particles (same amount as in Example 1 as a lipid amount) labeled with a fluorescent dye (DiI) and prepared in Comparative Example 2 were administered via the tail vein. The pemetrexed-containing lipid particles (1.5 mg / kg as a drug amount) labeled with a fluorescent dye (DiI) and prepared in Comparative Example 3 were administered via the tail vein. Furthermore, lipid particles containing doxorubicin hydrochloride (drug amount: 16.7 mg / kg) that were labeled with a fluorescent dye (DiI) and prepared in Comparative Example 4 were administered via the tail vein.
[0120] The animals were dissected 72 hours after administration, and femoral bone marrow was collected. The concentrations of DiI in the administered solution and tissues of the collected bone marrow were quantified using an HPLC (high performance liquid chromatography) fluorescence detector, and the bone marrow accumulation rate was calculated using the following formula 2. The bone marrow accumulation rate is expressed as the percentage of the administered lipid particles that accumulated in the bone marrow per 1 g of bone marrow (% injected dose / g) (also expressed as %ID / g). The measurement results are shown in each table.
[0121] Formula 2: Bone marrow accumulation rate (%ID / g) = DiI concentration in bone marrow (ng / g) / (DiI concentration in administration solution (ng / mL) × administration volume (mL)) × 100
[0122] [Table 1]
[0123] [Table 2]
[0124] [Table 3]
[0125] [Table 4]
[0126] Compared with the lipid particle compositions of Comparative Examples 2 to 4, the lipid particle compositions of Examples 1 to 25 of the present invention showed high bone marrow accumulation.
[0127] From Examples 3 to 5 and 22 to 24, the less DSPE-PEG added, the better the accumulation in bone marrow. Moreover, from Examples 10 to 13, the larger the particle size, the better the accumulation in bone marrow, but even small lipid particles of about 100 nm showed higher bone marrow accumulation than lipid particles not encapsulating panobinostat (empty liposomes). From Examples 14 to 17, the addition of anionic lipid improved bone marrow accumulation.
[0128] As shown in the analysis below, it is assumed that the lipid particles encapsulating panobinostat are recognized by macrophages, resulting in high accumulation in the bone marrow. All of the above factors are thought to indirectly contribute to increasing bone marrow accumulation by affecting the ease of recognition by macrophages. For example, a decrease in zeta potential due to the addition of anionic lipids has the effect of making the particles more easily recognized by scavenger receptors on macrophages, which is thought to lead to improved bone marrow accumulation.
[0129] <Measurement of panobinostat concentration in tissues> Panobinostat-containing lipid particles (4 mg / kg as drug amount) prepared in Examples 1, 2, 14, and 19 were administered to ICR mice (male, 7 weeks old) via the tail vein. In addition, the panobinostat solution (5 mg / kg) prepared in Comparative Example 1 was intraperitoneally administered to ICR mice (male, 7 weeks old). Assuming the dose in the efficacy test, the dose of the panobinostat-containing lipid particles prepared in Examples 1, 2, 14, and 19 was set to the maximum tolerated dose in a single administration, and the dose of the panobinostat solution prepared in Comparative Example 1 was set to the maximum tolerated dose in daily administration for 8 days.
[0130] Mice administered with the panobinostat-containing lipid particles prepared in Examples 1, 2, 14, and 19 were dissected 3, 6, 24, 72, and 168 hours after administration. Mice administered with the panobinostat solution prepared in Comparative Example 1 were dissected 1, 3, 6, 24, and 72 hours after administration, and blood, femoral bone marrow, and digestive tract (lower ileum) were collected. Blood was centrifuged at 800×g for 10 minutes to collect plasma. The digestive tract was homogenized by freeze-crushing. The collected plasma, bone marrow, and digestive tract were subjected to quantitative determination of the panobinostat concentration in tissues using liquid chromatography / mass spectrometry / mass spectrometry (LC / MS / MS). From the obtained changes in the panobinostat concentration in tissues, the area under the tissue concentration-time curve (AUC) up to infinity after a single dose was calculated using pharmacokinetic analysis software WinNonlin (registered trademark) (Certara). Furthermore, the bone marrow / gastrointestinal ratio of AUC in tissues was calculated using the following formula 1. The results are shown in FIG.
[0131] Formula 1: Bone marrow / gastrointestinal tract ratio = panobinostat AUC in the bone marrow / panobinostat AUC in the gastrointestinal tract = (area under the concentration-time curve in the bone marrow) / (area under the concentration-time curve in the gastrointestinal tract)
[0132] <Measurement of pemetrexed concentration in tissues> The pemetrexed-containing lipid particles prepared in Comparative Example 3 (drug amount: 1.5 mg / kg) were administered to ICR mice (male, 7 weeks old) via the tail vein.
[0133] For the mice administered with the pemetrexed-containing lipid particles prepared in Comparative Example 3, they were dissected at 24, 72, 120, and 168 hours after administration, and blood, femoral bone marrow, and the digestive tract (lower ileum) were collected. The pemetrexed concentration in the tissue was quantified in the same manner as panobinostat, and the AUC and the bone marrow / digestive tract ratio of the AUC in the tissue were calculated. The results are shown in Table 5.
[0134]
Table 5
[0135] From the above results, compared with the panobinostat solution prepared in Comparative Example 1 and the pemetrexed-containing lipid particles prepared in Comparative Example 3, the panobinostat-containing lipid particles prepared in Examples 1, 2, 14, and 19 showed a higher bone marrow / digestive tract ratio and better bone marrow accumulation in terms of the panobinostat AUC in the tissue.
[0136] <Pharmacodynamic test using Molm-13 orthotopic model mice> NOD / SCID mice (male, 8 weeks old) were immunosuppressed with cyclophosphamide (125 mg / kg, intraperitoneal administration, daily for 2 days) and rabbit anti-asialo GM1 antibody (Wako Pure Chemical Industries, Ltd.) (0.4 mg, intraperitoneal administration, single administration). 3×10 of Molm-13 cells, a human leukemia cell line 6The mice were transplanted intravenously and allowed to take root in the bone marrow. From the 8th day after transplantation, administration was started of the panobinostat-containing lipid particles prepared in Example 1 (8 mg / kg as drug amount, administered intravenously in the tail vein, administered once), the panobinostat solution prepared in Comparative Example 1 (5 mg / kg, administered intraperitoneally, administered daily for 8 days), and the lipid particles not containing panobinostat prepared in Comparative Example 2 as a negative control (lipid amount equivalent to 8 mg / kg of the panobinostat-containing lipid particles prepared in Example 1, administered intravenously in the tail vein, administered once). In addition, a group in which immunosuppression and transplantation were not performed was set as a non-transplantation group. The mice were dissected 16 days after transplantation (8 days after the start of administration) and femoral bone marrow was collected. The obtained bone marrow was treated with a hemolysis buffer to remove red blood cells, and then stained with PerCP-labeled anti-human CD45 antibody and DAPI (4,6-diamidino-2-phenylindole). PerCP stands for peridinin chlorophyll. Using flow cytometry, the proportion of leukemia cells (human CD45 positive, DAPI negative cells) in live bone marrow cells was measured, and the growth inhibitory activity against leukemia cells in Molm-13 orthotopic model mice was compared. The measurement results are shown in Figure 4.
[0137] The results in Figure 4 show that, compared to the panobinostat solution prepared in Comparative Example 1 and the lipid particles not containing panobinostat prepared in Comparative Example 2, the panobinostat-containing lipid particles prepared in Example 1 exhibited high inhibitory activity against the proliferation of leukemia cells, and that the effect was dose-dependent.
[0138] <Analysis of bone marrow macrophage numbers and intracellular lipid particle amounts> The DiI-labeled lipid particles containing panobinostat prepared in Example 2 were administered to ICR mice (male, 7 weeks old) at a drug dose of 6 mg / kg via the tail vein. Mice were dissected after non-administration, administration 6 hours, and administration 96 hours, and femoral bone marrow was collected. The bone marrow obtained was treated with hemolysis buffer to remove red blood cells, and then stained with Alexa fluor (registered trademark) 647-labeled anti-mouse F4 / 80 antibody, FITC-labeled anti-mouse CD11b antibody, and DAPI. FITC stands for fluorescein isothiocyanate. The proportion of macrophages (mouse F4 / 80 positive, mouse CD11 positive, DAPI negative cells) in live bone marrow cells was measured using flow cytometry. Furthermore, the amount of lipid particles taken up by cells was analyzed for samples 96 hours after administration, using the fluorescence intensity of DiI in the cells as an index. The analysis results are shown in FIG. 5. In FIG. 5, Mφ stands for macrophages.
[0139] The results in Figure 5 show that the number of macrophages in the bone marrow increased over time after administration of the panobinostat-containing lipid particles prepared in Example 2, and that the panobinostat-containing lipid particles were taken up by the increased macrophages.
[0140] <Analysis of cytokine expression in bone marrow> Panobinostat-containing lipid particles prepared in Example 2 (4 mg / kg as drug amount, administered intravenously in the tail vein, administered once) and panobinostat solution prepared in Comparative Example 1 (5 mg / kg, administered intraperitoneally, administered once) were administered to ICR mice (male, 7 weeks old), and the mice were dissected 72 hours after administration to collect femoral bone marrow. In addition, femoral bone marrow was also obtained from non-administered mice as a negative control. After adding PBS in an amount three times the weight of the bone marrow, the mixture was centrifuged at 300×g for 5 minutes to collect the supernatant. The protein concentration of the obtained bone marrow supernatant was measured by the BCA method (bicinchoninic acid method), and each sample was diluted to a protein concentration of 8 mg / mL. The cytokine concentration in each sample was quantified using the Bio-Plex mouse cytokine GI23-Plex panel and the Bio-Plex200 system (Bio-Rad). The relative expression change when the average value of the cytokine expression level in the non-administered mice was set to 1 was shown. The analysis results are shown in FIG. 6.
[0141] In Figure 6, IL stands for interleukin, G-CSF stands for granulocyte colony-stimulating factor, GM-CSF stands for granulocyte-monocyte colony-stimulating factor, IFN stands for interferon, KC stands for keratinocyte chemoattractant, MCP stands for Monocyte Chemotactic Protein, MIP stands for Macrophage inflammatory protein, PANTES stands for regulated on activation normal T expressed and secreted, and TNF stands for tumor necrosis factor.
[0142] 6, compared with the non-administration case, the administration of the panobinostat-containing lipid particles prepared in Example 2 or the panobinostat solution prepared in Comparative Example 1 tended to increase cytokine expression, and cytokine expression was further enhanced in the panobinostat-containing lipid particles prepared in Example 2. Increased cytokine expression is thought to be a factor in the accumulation of macrophages in the bone marrow.
Claims
1. A lipid particle composition comprising panobinostat or a salt thereof, the lipid particle comprising phospholipids and cholesterols, The average particle size of the lipid particles is 141 nm to 500 nm; the phospholipid is sphingomyelin or dihydrosphingomyelin; the content of cholesterols is 30 mol % to 45 mol % based on the total amount of lipids constituting the lipid particles; The lipid particle composition further comprising a polyethylene glycol lipid.
2. 2. The lipid particle composition according to claim 1, wherein the content of the polyethylene glycol lipid is 0.1 to 1 mol % based on the total amount of lipids constituting the lipid particle.
3. A lipid particle composition comprising panobinostat or a salt thereof, the lipid particle comprising phospholipids and cholesterols, The average particle size of the lipid particles is 141 nm to 500 nm; the phospholipid is sphingomyelin or dihydrosphingomyelin; the content of cholesterols is 30 mol % to 45 mol % based on the total amount of lipids constituting the lipid particles; A lipid particle composition comprising an anionic lipid and being substantially free of polyethylene glycol lipids.
4. The lipid particle composition according to claim 3, wherein the content of the anionic lipid is 0.1 to 10 mol % based on the total amount of lipids constituting the lipid particle.
Citation Information
Patent Citations
Remote loading of sparingly water-soluble drugs into liposomes
WO2014121211A2
